Connected care enters a vital security frontier

Tern plc

As hospitals deploy more connected devices, the real vulnerability is no longer the network but the devices themselves. Device Authority is targeting this exact gap, offering a way to manage trust, identity and compliance at scale, all without manual oversight.

At the heart of the offering is automation of device trust and lifecycle management. For manufacturers and operators of connected medical equipment, the challenge lies in provisioning, rotating, revoking and monitoring credentials across large fleets, often in highly regulated settings. The KeyScaler platform is branded as delivering exactly that: seamless device registration, certificate management, enforcing Zero Trust policy at the edge, and continuous assurance of connected devices. By automating those security operations, the firm aims to reduce human error, accelerate incident response and support compliance across healthcare networks.

The company’s positioning in IoMT complements its broader IoT/OT play, suggesting opportunity for cross‑industry efficiencies. With connected medical devices trending upwards, and hospital networks under increasing pressure to secure them against threat actors and compliance breaches, the addressable market is set to expand.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

What HCPs say could reveal prescribing intent

Talking Medicines is using AI to analyse HCP conversations and identify the clinical and practical factors that may influence prescribing intent.

AI control of machines raises new security questions

AI is gaining the ability to control physical equipment, but establishing that machines are genuine, authorised and secure will be an important part of making this technology safe to deploy.

CAR-T therapy brings new approach to multiple myeloma treatment

CAR-T therapy is being used in multiple myeloma and is being studied earlier in the treatment pathway, with research focused on improving durability, safety and access.

Tern cuts H1 loss by 60% as portfolio growth and funding strengthen

Tern reduced its first-half loss by 60%, with net asset value improving and further fundraising strengthening the balance sheet. Additional funding has supported Talking Medicines and Device Authority, while continued progress across the portfolio provides further scope for value creation.

AI control of machines creates a new market for device trust

AI is beginning to control physical machines, increasing demand for technology that can verify device identity before those machines are allowed to act.

Peptide drug development expands beyond GLP-1

GLP-1 success is widening interest in peptide drug development, with the next phase focused on proving clinical value across new therapeutic areas.

Search